Ustekinumab. Análisis de efectos adversos infecciosos
Ustekinumab. Analysis of Rates of Infection
P. Herranz-Pinto
, E. Sendagorta
Corresponding author
Servicio de Dermatología. Hospital Universitario La Paz. Madrid. España
Read
4291
Timeswas read the article
2231
Total PDF
2060
Total HTML
Share statistics
array:23 [ "pii" => "S0001731012700054" "issn" => "00017310" "doi" => "10.1016/S0001-7310(12)70005-4" "estado" => "S300" "fechaPublicacion" => "2012-10-01" "aid" => "70005" "copyright" => "Academia Española de Dermatología y Venereología" "copyrightAnyo" => "2012" "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Actas Dermosifiliogr. 2012;103 Supl 2:25-30" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 1163 "formatos" => array:2 [ "HTML" => 621 "PDF" => 542 ] ] "itemSiguiente" => array:18 [ "pii" => "S0001731012700066" "issn" => "00017310" "doi" => "10.1016/S0001-7310(12)70006-6" "estado" => "S300" "fechaPublicacion" => "2012-10-01" "aid" => "70006" "copyright" => "Academia Española de Dermatología y Venereología" "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Actas Dermosifiliogr. 2012;103 Supl 2:31-8" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 1299 "formatos" => array:2 [ "HTML" => 740 "PDF" => 559 ] ] "es" => array:10 [ "idiomaDefecto" => true "titulo" => "Ustekinumab y seguridad cardiovascular" "tienePdf" => "es" "tieneTextoCompleto" => 0 "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "31" "paginaFinal" => "38" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Ustekinumab and Cardiovascular Safety" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "J.C. Ruiz-Carrascosa" "autores" => array:1 [ 0 => array:2 [ "nombre" => "J.C." "apellidos" => "Ruiz-Carrascosa" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731012700066?idApp=UINPBA000044" "url" => "/00017310/00000103000000S2/v1_201304241722/S0001731012700066/v1_201304241722/es/main.assets" ] "itemAnterior" => array:18 [ "pii" => "S0001731012700042" "issn" => "00017310" "doi" => "10.1016/S0001-7310(12)70004-2" "estado" => "S300" "fechaPublicacion" => "2012-10-01" "aid" => "70004" "copyright" => "Academia Española de Dermatología y Venereología" "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Actas Dermosifiliogr. 2012;103 Supl 2:16-24" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 1703 "formatos" => array:2 [ "HTML" => 1283 "PDF" => 420 ] ] "es" => array:10 [ "idiomaDefecto" => true "titulo" => "Eficacia de ustekinumab en el tratamiento de la psoriasis moderada-grave" "tienePdf" => "es" "tieneTextoCompleto" => 0 "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "16" "paginaFinal" => "24" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Efficacy of Ustekinumab in the Treatment of Moderate-Severe Psoriasis" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "R. Jiménez-Puya, J.C. Moreno" "autores" => array:2 [ 0 => array:2 [ "nombre" => "R." "apellidos" => "Jiménez-Puya" ] 1 => array:2 [ "nombre" => "J.C." "apellidos" => "Moreno" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731012700042?idApp=UINPBA000044" "url" => "/00017310/00000103000000S2/v1_201304241722/S0001731012700042/v1_201304241722/es/main.assets" ] "es" => array:12 [ "idiomaDefecto" => true "titulo" => "Ustekinumab. Análisis de efectos adversos infecciosos" "tieneTextoCompleto" => 0 "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "25" "paginaFinal" => "30" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "P. Herranz-Pinto, E. Sendagorta" "autores" => array:2 [ 0 => array:4 [ "nombre" => "P." "apellidos" => "Herranz-Pinto" "email" => array:1 [ 0 => "pherranzp@gmail.com" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">¿</span>" "identificador" => "cor0005" ] ] ] 1 => array:2 [ "nombre" => "E." "apellidos" => "Sendagorta" ] ] "afiliaciones" => array:1 [ 0 => array:1 [ "entidad" => "Servicio de Dermatología. Hospital Universitario La Paz. Madrid. España" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Autor para correspondencia." ] ] ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Ustekinumab. Analysis of Rates of Infection" ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "PalabrasClave" => array:2 [ "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec85088" "palabras" => array:5 [ 0 => "Ustekinumab" 1 => "Psoriasis" 2 => "Efectos adversos" 3 => "Seguridad" 4 => "Infecciones" ] ] ] "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec85089" "palabras" => array:5 [ 0 => "Ustekinumab" 1 => "Psoriasis" 2 => "Adverse effects" 3 => "Safety" 4 => "Infections" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "es" => array:2 [ "titulo" => "Resumen" "resumen" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Ustekinumab es el primer representante de un nuevo grupo de fármacos biológicos, cuyo mecanismo de acción principal es la inhibición selectiva de la actividad de las interleucinas 12 y 23. A pesar de ser la terapia de uso más reciente en dermatología, es el fármaco que mayor número de pacientes ha aportado en su desarrollo clínico en psoriasis. Gracias a esta experiencia acumulada, se ha confirmado que el perfil de seguridad de ustekinumab frente a eventos infecciosos demuestra un riesgo similar a placebo y equiparable a la población general en cuanto a incidencia absoluta, infecciones severas y requerimientos de antibioterapia adicional. Este comportamiento inicial se confirma durante el seguimiento a 3 y 4 años en pacientes con psoriasis moderada a severa.</p><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">A pesar de este perfil favorable de seguridad, el carácter inmunosupresor selectivo de ustekinumab aconseja mantener un seguimiento estricto de los pacientes en tratamiento, como el despistaje de infecciones activas o latentes, similar a los aplicados en el caso de los fármacos anti factor de necrosis tumoral.</p>" ] "en" => array:2 [ "titulo" => "Abstract" "resumen" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Ustekinumab is the first of a new class of biologic agents whose main mechanism of action involves the selective inhibition of IL-12 and IL-23. Although ustekinumab is the latest biologic to be approved for use in dermatology, its approval was based on the largest clinical development program conducted to date in psoriasis. Safety data accumulated during the clinical development phase showed the risk of infection to be similar in patients in the ustekinumab and placebo groups. The use of additional antibiotics and the rates of overall infection and serious infection in patients on ustekinumab and the general population were also comparable. Subsequent studies confirmed the safety of this drug in patients with moderate to severe psoriasis treated for 3 or 4 years. Despite its favorable safety profile, ustekinumab is a selective immunosuppressant. Clinicians should therefore closely monitor patients and apply screening measures similar to those used during anti-TNF therapy to detect de novo infections or the reactivation of latent infections.</p>" ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:16 [ 0 => array:3 [ "identificador" => "bib1" "etiqueta" => "1." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Psoriasis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "F.O. Nestle" 1 => "D.H. Kaplan" 2 => "J. Barker" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMra0804595" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2009" "volumen" => "361" "paginaInicial" => "496" "paginaFinal" => "509" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19641206" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib2" "etiqueta" => "2." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "New developments in the treatment of psoriasis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "M. Lebwohl" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Arch Dermatol." "fecha" => "2002" "volumen" => "138" "paginaInicial" => "686" "paginaFinal" => "688" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12020234" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib3" "etiqueta" => "3." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The IL-23/Th17 axis in the immunopathogenesis of psoriasis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "A. Di Cesare" 1 => "P. Di Meglio" 2 => "F.O. Nestle" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/jid.2009.59" "Revista" => array:6 [ "tituloSerie" => "J Invest Dermatol" "fecha" => "2009" "volumen" => "129" "paginaInicial" => "1339" "paginaFinal" => "1350" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19322214" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib4" "etiqueta" => "4." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 1)" "autores" => array:1 [ 0 => array:3 [ "colaboracion" => "PHOENIX 1 study investigators" "etal" => true "autores" => array:6 [ 0 => "C.L. Leonardi" 1 => "A.B. Kimball" 2 => "K.A. Papp" 3 => "N. Yeilding" 4 => "C. Guzzo" 5 => "Y. Wang" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(08)60725-4" "Revista" => array:6 [ "tituloSerie" => "Lancet" "fecha" => "2008" "volumen" => "371" "paginaInicial" => "1665" "paginaFinal" => "1674" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18486739" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib5" "etiqueta" => "5." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 2)" "autores" => array:1 [ 0 => array:3 [ "colaboracion" => "PHOENIX 2 study investigators" "etal" => true "autores" => array:6 [ 0 => "K.A. Papp" 1 => "R.G. Langley" 2 => "M. Lebwohl" 3 => "G.G. Krueger" 4 => "P. Szapary" 5 => "N. Yeilding" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(08)60726-6" "Revista" => array:6 [ "tituloSerie" => "Lancet" "fecha" => "2008" "volumen" => "371" "paginaInicial" => "1675" "paginaFinal" => "1684" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18486740" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib6" "etiqueta" => "6." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Ustekinumab: treatment of adult moderate-to-severe chronic plaque psoriasis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "J.V. Scanlon" 1 => "B.P. Exter" 2 => "M. Steinberg" 3 => "C.I. Jarvis" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1345/aph.1M151" "Revista" => array:6 [ "tituloSerie" => "Ann Pharmacother" "fecha" => "2009" "volumen" => "43" "paginaInicial" => "1456" "paginaFinal" => "1465" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19671802" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib7" "etiqueta" => "7." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Leonardi C GL, Wasel N, Yeilding N, Szapary P, Hsu MC, Langley R, et al. Characterization of infections associated with ustekinumab in moderate to severe psoriasis patients. PO49. Psoriasis 2010, Congress of the International Psoriasis Network. Paris, 1–4 Jul 2010." ] ] ] 7 => array:3 [ "identificador" => "bib8" "etiqueta" => "8." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Gordon K LC, Griffiths CEM, Szapary P, Yeilding N, Hsu MC, Wasel N, et al. Ustekinumab safety update: cumulative experience from longer term follow-up of patients treated in the ustekinumab psoriasis clinical development program. Psoriasis 2010, Congress of the International Psoriasis Network. París, 1–4 Jul 2010. Poster 047." ] ] ] 8 => array:3 [ "identificador" => "bib9" "etiqueta" => "9." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Reich K LC, Griffiths CEM, Szapary PO, Wasfi Y, Hsu MC, Gordon K on behalf of the PHOENIX 1 & 2 and ACCEPT investigators. Update on the cumulative safety experience of ustekinumab: results from the ustekinumab psoriasis clinical development program with up to 4 years of follow-up. FC07-03 World Congress of Dermatology. Seúl, Corea, 2011." ] ] ] 9 => array:3 [ "identificador" => "bib10" "etiqueta" => "10." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "G. Trinchieri" 1 => "S. Pflanz" 2 => "R.A. Kastelein" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Immunity" "fecha" => "2003" "volumen" => "19" "paginaInicial" => "641" "paginaFinal" => "644" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/14614851" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib11" "etiqueta" => "11." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Inborn errors of IL-12/23- and IFN-gamma-mediated immunity: molecular, cellular, and clinical features" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "O. Filipe-Santos" 1 => "J. Bustamante" 2 => "A. Chapgier" 3 => "G. Vogt" 4 => "L. De Beaucoudrey" 5 => "J. Feinberg" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.smim.2006.07.010" "Revista" => array:6 [ "tituloSerie" => "Semin Immunol" "fecha" => "2006" "volumen" => "18" "paginaInicial" => "347" "paginaFinal" => "361" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16997570" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib12" "etiqueta" => "12." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Genetic dissection of immunity to mycobacteria: the human model" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "J.L. Casanova" 1 => "L. Abel" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1146/annurev.immunol.20.081501.125851" "Revista" => array:6 [ "tituloSerie" => "Annu Rev Immunol" "fecha" => "2002" "volumen" => "20" "paginaInicial" => "581" "paginaFinal" => "620" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11861613" "web" => "Medline" ] ] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib13" "etiqueta" => "13." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The role of interleukin-12 in human infectious diseases: only a faint signature" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "C. Fieschi" 1 => "J.L. Casanova" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/eji.200324038" "Revista" => array:6 [ "tituloSerie" => "Eur J Immunol" "fecha" => "2003" "volumen" => "33" "paginaInicial" => "1461" "paginaFinal" => "1464" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12778462" "web" => "Medline" ] ] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib14" "etiqueta" => "14." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Interleukin (IL)-12 and IL-23 are key cytokines for immunity against Salmonella in humans" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "C. MacLennan" 1 => "C. Fieschi" 2 => "D.A. Lammas" 3 => "C. Picard" 4 => "S.E. Dorman" 5 => "O. Sanal" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1086/425021" "Revista" => array:6 [ "tituloSerie" => "J Infect Dis" "fecha" => "2004" "volumen" => "190" "paginaInicial" => "1755" "paginaFinal" => "1757" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15499529" "web" => "Medline" ] ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib15" "etiqueta" => "15." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Revisiting human IL-12Rβ1 deficiency: a survey of 141 patients from 30 countries" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "L. De Beaucoudrey" 1 => "A. Samarina" 2 => "J. Bustamante" 3 => "A. Cobat" 4 => "S. Boisson- Dupuis" 5 => "J. Feinberg" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Medicine (Baltimore)" "fecha" => "2010" "volumen" => "89" "paginaInicial" => "381" "paginaFinal" => "402" ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib16" "etiqueta" => "16." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Herranz-Pinto P S-CE, Casado-Verrier B, Gómez-Fernández C, Alonso-Pacheco ML, Casado-Jiménez ML. Psoriasis en pacientes con coinfección VIH-VHC. Primer año de tratamiento con ustekinumab. Póster Congreso Nacional de Dermatología 2011. Santiago de Compostela, 2011." ] ] ] ] ] ] ] ] "idiomaDefecto" => "es" "url" => "/00017310/00000103000000S2/v1_201304241722/S0001731012700054/v1_201304241722/es/main.assets" "Apartado" => null "PDF" => "https://static.elsevier.es/multimedia/00017310/00000103000000S2/v1_201304241722/S0001731012700054/v1_201304241722/es/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731012700054?idApp=UINPBA000044" ]
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 November | 4 | 10 | 14 |
| 2024 October | 31 | 37 | 68 |
| 2024 September | 29 | 22 | 51 |
| 2024 August | 49 | 44 | 93 |
| 2024 July | 41 | 27 | 68 |
| 2024 June | 55 | 28 | 83 |
| 2024 May | 47 | 45 | 92 |
| 2024 April | 44 | 31 | 75 |
| 2024 March | 29 | 30 | 59 |
| 2024 February | 23 | 27 | 50 |
| 2024 January | 18 | 25 | 43 |
| 2023 December | 22 | 17 | 39 |
| 2023 November | 26 | 21 | 47 |
| 2023 October | 24 | 18 | 42 |
| 2023 September | 22 | 27 | 49 |
| 2023 August | 26 | 22 | 48 |
| 2023 July | 21 | 26 | 47 |
| 2023 June | 12 | 33 | 45 |
| 2023 May | 9 | 22 | 31 |
| 2023 April | 17 | 25 | 42 |
| 2023 March | 15 | 33 | 48 |
| 2023 February | 17 | 22 | 39 |
| 2023 January | 17 | 31 | 48 |
| 2022 December | 22 | 39 | 61 |
| 2022 November | 23 | 34 | 57 |
| 2022 October | 69 | 26 | 95 |
| 2022 September | 49 | 40 | 89 |
| 2022 August | 44 | 45 | 89 |
| 2022 July | 22 | 45 | 67 |
| 2022 June | 15 | 55 | 70 |
| 2022 May | 22 | 38 | 60 |
| 2022 April | 31 | 30 | 61 |
| 2022 March | 20 | 42 | 62 |
| 2022 February | 20 | 26 | 46 |
| 2022 January | 21 | 36 | 57 |
| 2021 December | 15 | 32 | 47 |
| 2021 November | 22 | 41 | 63 |
| 2021 October | 21 | 51 | 72 |
| 2021 September | 20 | 44 | 64 |
| 2021 August | 25 | 28 | 53 |
| 2021 July | 11 | 24 | 35 |
| 2021 June | 19 | 49 | 68 |
| 2021 May | 18 | 40 | 58 |
| 2021 April | 49 | 63 | 112 |
| 2021 March | 42 | 39 | 81 |
| 2021 February | 26 | 24 | 50 |
| 2021 January | 25 | 13 | 38 |
| 2020 December | 15 | 17 | 32 |
| 2020 November | 10 | 17 | 27 |
| 2020 October | 24 | 12 | 36 |
| 2020 September | 11 | 6 | 17 |
| 2020 August | 21 | 13 | 34 |
| 2020 July | 19 | 11 | 30 |
| 2020 June | 24 | 22 | 46 |
| 2020 May | 21 | 32 | 53 |
| 2020 April | 20 | 15 | 35 |
| 2020 March | 25 | 17 | 42 |
| 2020 January | 0 | 5 | 5 |
| 2019 December | 0 | 3 | 3 |
| 2019 November | 0 | 1 | 1 |
| 2019 October | 0 | 2 | 2 |
| 2019 September | 0 | 5 | 5 |
| 2019 August | 0 | 1 | 1 |
| 2019 July | 0 | 6 | 6 |
| 2019 June | 0 | 3 | 3 |
| 2019 May | 0 | 23 | 23 |
| 2019 April | 0 | 25 | 25 |
| 2019 February | 1 | 5 | 6 |
| 2019 January | 0 | 3 | 3 |
| 2018 December | 1 | 7 | 8 |
| 2018 November | 0 | 2 | 2 |
| 2018 October | 0 | 3 | 3 |
| 2018 August | 0 | 6 | 6 |
| 2018 June | 0 | 4 | 4 |
| 2018 February | 13 | 5 | 18 |
| 2018 January | 12 | 4 | 16 |
| 2017 December | 12 | 9 | 21 |
| 2017 November | 10 | 7 | 17 |
| 2017 October | 8 | 5 | 13 |
| 2017 September | 9 | 7 | 16 |
| 2017 August | 6 | 10 | 16 |
| 2017 July | 12 | 3 | 15 |
| 2017 June | 14 | 6 | 20 |
| 2017 May | 8 | 9 | 17 |
| 2017 April | 18 | 16 | 34 |
| 2017 March | 11 | 25 | 36 |
| 2017 February | 9 | 9 | 18 |
| 2017 January | 10 | 21 | 31 |
| 2016 December | 23 | 11 | 34 |
| 2016 November | 23 | 12 | 35 |
| 2016 October | 22 | 9 | 31 |
| 2016 September | 30 | 13 | 43 |
| 2016 August | 29 | 15 | 44 |
| 2016 July | 18 | 8 | 26 |
| 2016 June | 0 | 4 | 4 |
| 2016 May | 0 | 9 | 9 |
| 2016 April | 1 | 1 | 2 |
| 2016 March | 0 | 2 | 2 |
| 2016 February | 0 | 4 | 4 |
| 2016 January | 0 | 16 | 16 |
| 2015 December | 0 | 19 | 19 |
| 2015 November | 5 | 16 | 21 |
| 2015 October | 3 | 5 | 8 |
| 2015 September | 5 | 13 | 18 |
| 2015 August | 6 | 7 | 13 |
| 2015 July | 22 | 3 | 25 |
| 2015 June | 21 | 3 | 24 |
| 2015 May | 45 | 19 | 64 |
| 2015 April | 30 | 12 | 42 |
| 2015 March | 26 | 20 | 46 |
| 2015 February | 29 | 10 | 39 |
| 2015 January | 33 | 12 | 45 |
| 2014 December | 34 | 8 | 42 |
| 2014 November | 23 | 11 | 34 |
| 2014 October | 34 | 29 | 63 |
| 2014 September | 0 | 2 | 2 |
| 2014 May | 1 | 0 | 1 |
| 2014 January | 0 | 1 | 1 |
| 2013 September | 1 | 1 | 2 |
| 2013 June | 0 | 1 | 1 |
| 2013 May | 1 | 1 | 2 |
| 2013 April | 1 | 2 | 3 |
| 2013 February | 1 | 2 | 3 |
| 2013 January | 0 | 1 | 1 |
Show all
